JP7595413B2 - １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 - Google Patents

１５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 Download PDF

Info

Publication number
JP7595413B2
JP7595413B2 JP2019528506A JP2019528506A JP7595413B2 JP 7595413 B2 JP7595413 B2 JP 7595413B2 JP 2019528506 A JP2019528506 A JP 2019528506A JP 2019528506 A JP2019528506 A JP 2019528506A JP 7595413 B2 JP7595413 B2 JP 7595413B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
pgdh
body weight
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502070A5 (cg-RX-API-DMAC7.html
JP2020502070A (ja
Inventor
マーコウィッツ，サンフォード
ジン ホ，ウォン
ピー． フィンク，ステファン
バラダン，ビナイ
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2020502070A publication Critical patent/JP2020502070A/ja
Publication of JP2020502070A5 publication Critical patent/JP2020502070A5/ja
Application granted granted Critical
Publication of JP7595413B2 publication Critical patent/JP7595413B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019528506A 2016-11-30 2017-11-30 １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 Active JP7595413B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662428259P 2016-11-30 2016-11-30
US62/428,259 2016-11-30
US201762510166P 2017-05-23 2017-05-23
US62/510,166 2017-05-23
PCT/US2017/063959 WO2018102552A1 (en) 2016-11-30 2017-11-30 Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2020502070A JP2020502070A (ja) 2020-01-23
JP2020502070A5 JP2020502070A5 (cg-RX-API-DMAC7.html) 2021-01-28
JP7595413B2 true JP7595413B2 (ja) 2024-12-06

Family

ID=62242708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528506A Active JP7595413B2 (ja) 2016-11-30 2017-11-30 １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用

Country Status (4)

Country Link
US (2) US11690847B2 (cg-RX-API-DMAC7.html)
EP (1) EP3548035A4 (cg-RX-API-DMAC7.html)
JP (1) JP7595413B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018102552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
HUE068315T2 (hu) 2014-01-21 2024-12-28 Neurocrine Biosciences Inc CRF1 receptor antagonisták kongenitális adrenális hiperplázia kezelésére
CN118059093A (zh) 2015-03-08 2024-05-24 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
EP3576737A4 (en) 2017-02-06 2021-04-21 Case Western Reserve University COMPOSITIONS AND METHODS OF MODULATING THE ACTIVITY OF SHORT CHAIN DEHYDROGENASE
EP3606520A4 (en) 2017-04-07 2021-01-06 Case Western Reserve University INHIBITORS OF SHORT CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF CORONARY DISEASES
EP3883577A4 (en) * 2018-11-21 2022-06-15 Case Western Reserve University COMPOSITIONS AND METHODS FOR MODULATION OF SHORT CHAIN DEHYDROGENASE ACTIVITY
TW202446384A (zh) 2018-12-07 2024-12-01 美商紐羅克里生物科學有限公司 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
EP3922247A4 (en) * 2019-01-08 2022-10-12 Kyorin Pharmaceutical Co., Ltd. 15-PGDH INHIBITOR
CA3152590A1 (en) 2019-09-27 2021-04-01 Evan Smith Crf receptor antagonists and methods of use
AU2021211732A1 (en) 2020-01-23 2022-08-25 Myoforte Therapeutics, Inc. PGDH inhibitors and methods of making and using
CA3183262A1 (en) 2020-05-20 2021-11-25 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
AU2021396543A1 (en) * 2020-12-09 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of prostaglandin degrading enzyme 15-pgdh to improve joint structure and function
WO2025148611A1 (zh) * 2024-01-12 2025-07-17 新牛（郑州）生物科技有限公司 肿瘤抗原肽融合蛋白及其组合物的基因工程化递送和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536855A (ja) 2005-04-15 2008-09-11 ジェネンテック・インコーポレーテッド 炎症性腸疾患（ｉｂｄ）の治療
WO2015065716A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2015514770A (ja) 2012-04-16 2015-05-21 ケース ウエスタン リザーブ ユニバーシティ １５−ｐｇｄｈ活性を調節する組成物および方法

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3461461A (en) 1965-11-01 1969-08-12 Upjohn Co 6-amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidines
AU3532984A (en) 1983-11-14 1985-05-23 Dow Chemical Company, The Method of preparing 1, 2, 4-triazolo (1, 5-a)- pyrimidine-2-sulfonyl chlorides
SE8405924L (sv) 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
EP0271273A3 (en) 1986-12-08 1989-07-12 Merck & Co. Inc. Thieno-and furopyridine sulfonamides
US4904672A (en) 1987-01-30 1990-02-27 Merck & Co., Inc. Derivatives of 3-hydroxyazabenzo[b]thiophene useful as 5-lipoxygenase inhibitors
GB8709248D0 (en) 1987-04-16 1987-05-20 Wyeth John & Brother Ltd Azo compounds
US4910226A (en) 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3812177A1 (de) 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
LU87308A1 (fr) 1988-08-01 1990-03-13 Oreal Nouveaux derives de diamino-2,4 pyrimidine oxyde-3 et leur utilisation pour le traitement et la prevention de la chute des cheveux
AU4500889A (en) * 1988-12-02 1990-06-26 Upjohn Company, The Minoxidil and vasoconstrictor compositions for treating alopecia
ATE119163T1 (de) 1989-01-11 1995-03-15 Ciba Geigy Ag Antidots zur verbesserung der kulturpflanzenvertäglichkeit agrochemischer wirkstoffe.
JP2821690B2 (ja) 1989-06-16 1998-11-05 日本ゼオン株式会社 医療用チューブ
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
FR2651122B1 (fr) 1989-08-29 1994-10-28 Oreal Compositions destinees a etre utilisees pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives de l'amino-2 pyrimidine oxyde-3 et nouveaux composes derives de l'amino-2 pyrimidine oxyde-3.
US5480913A (en) 1989-09-27 1996-01-02 Arch Development Corporation Anti-androgen compounds
EP0434624B1 (de) 1989-12-22 1995-02-08 Ciba-Geigy Ag Triazolylsulfonamide
US5217521A (en) 1989-12-22 1993-06-08 Ciba-Geigy Corporation Triazolylsulfonamides
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
FR2662607B1 (fr) 1990-05-30 1992-08-28 Oreal Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 .
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2677884B1 (fr) 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
FR2678929A1 (fr) 1991-07-11 1993-01-15 Oreal Compositions pour freiner la chute des cheveux et pour induire et stimuler leur croissance a base de derives de 2,4-diamino pyrimidine 3-oxyde, nouveaux derives 2,4-diamino pyrimidine 3-oxyde.
FR2683531B1 (fr) 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
AU3262593A (en) 1992-01-11 1993-08-03 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US5445164A (en) 1993-05-11 1995-08-29 Gynetech, Inc. Cervical tissue sampling device
EP0722331A4 (en) 1993-08-25 1997-10-01 Systemix Inc METHOD FOR PRODUCING A POPULATION OF HIGHLY ENRICHED HEMATOPOIETIC STEM CELLS
TW369521B (en) 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
FR2711060B1 (fr) 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
FR2719481B1 (fr) 1994-05-05 1996-05-31 Oreal Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
US5516779A (en) 1994-06-08 1996-05-14 Merck & Co., Inc. 17β-substituted-6-azasteroid derivatives useful as 5α-reductase inhibitors
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5807895A (en) 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
US5529769A (en) 1994-12-20 1996-06-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing betulinic acid
FR2732597B1 (fr) 1995-04-05 1997-05-16 Oreal Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
US5631282A (en) 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
FR2739553B1 (fr) 1995-10-06 1998-01-02 Oreal Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
JP3049593B2 (ja) 1996-05-01 2000-06-05 株式会社ビメーク 育毛・養毛剤
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
AU750039B2 (en) 1997-02-04 2002-07-11 Murray A. Johnstone Method of enhancing hair growth
JP3217293B2 (ja) 1997-04-17 2001-10-09 株式会社アールテック・ウエノ 発毛・育毛剤
CA2295595A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
WO1999031125A1 (en) 1997-12-12 1999-06-24 University Of Southern California Wound healing compositions
US6214533B1 (en) 1998-04-10 2001-04-10 Konica Corporation Thermally developable photosensitive material
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US20040241727A1 (en) 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of schizophrenia related gene transcripts in blood
US20040241726A1 (en) 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US8068897B1 (en) 1999-03-01 2011-11-29 Gazdzinski Robert F Endoscopic smart probe and method
WO2000054808A1 (fr) 1999-03-16 2000-09-21 Toray Industries, Inc. Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
WO2001017479A2 (en) 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating prostate disorders
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2001072268A1 (en) 2000-03-31 2001-10-04 Toray Industries, Inc. Hair growth or hair formation controlling agents
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
FR2812191B1 (fr) 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812190B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
EE200300470A (et) 2001-03-30 2004-02-16 Pfizer Products Inc. Aldoosreduktaasi püridasinooninhibiitorid
US7004913B1 (en) 2001-05-04 2006-02-28 Cdx Laboratories, Inc. Retractable brush for use with endoscope for brush biopsy
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US20030096823A1 (en) 2001-11-16 2003-05-22 Beryl Asp Method for the treatment of cardiotoxicity induced by antitumor compounds
JP2003286171A (ja) 2002-03-28 2003-10-07 Sumitomo Pharmaceut Co Ltd Ｐａｒ阻害剤
US7320967B2 (en) 2002-04-23 2008-01-22 L'oreal Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair
FR2838641B1 (fr) 2002-04-23 2005-12-23 Oreal Composition cosmetique, procede de traitement cosmetique et preparation d'une composition pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
CA2499491A1 (en) 2002-09-20 2004-04-01 Seiji Kagawa Shape-memory laminated polybutylene terephthalate film, production process and use thereof, and process for production of polybutylene terephthalate film
FR2845000B1 (fr) 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
JP2006505559A (ja) 2002-10-18 2006-02-16 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６受容体親和性を持つ４−ピペラジニルベンゼンスルホニルインドール
FR2845917B1 (fr) 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
US7105117B2 (en) 2003-01-06 2006-09-12 General Motors Corporation Manufacturing method for increasing thermal and electrical conductivities of polymers
EP1587486A2 (en) 2003-01-15 2005-10-26 L'oreal Care or make-up composition comprising a 2-alkylideneaminooxyacetamide, its use for stimulating the growth of the hair or eyelashes and/or slowing down their loss
WO2004073594A2 (fr) 2003-02-12 2004-09-02 L'oreal Utilisation d’un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
US7189724B2 (en) 2003-04-15 2007-03-13 Valeant Research And Development Quinoxaline derivatives having antiviral activity
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
CN1589793A (zh) 2003-07-24 2005-03-09 山东绿叶天然药物研究开发有限公司 鞣酸小檗碱在制备治疗溃疡性结肠炎药物中的应用
JP4783731B2 (ja) 2003-08-29 2011-09-28 ヴァーナリス（ケンブリッジ）リミテッド ピリミドチオフェン化合物
US20050187221A1 (en) 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
TW200512298A (en) 2003-09-24 2005-04-01 Oncotherapy Science Inc Method of diagnosing breast cancer
WO2005030773A1 (ja) 2003-09-26 2005-04-07 Dainippon Sumitomo Pharma Co., Ltd. 新規ピラゾロピリミジン誘導体
FR2860431A1 (fr) 2003-10-02 2005-04-08 Oreal Composition capillaire ou de mascara contenant un compose azoique, son utilisation pour stimuler ou induire la pousse des cheveux ou des cils et/ou freiner leur chute
US20050209181A1 (en) 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
WO2005066265A1 (en) 2003-12-31 2005-07-21 Basell Poliolefine Italia S.R.L. Filled olefin polymer compositions having improved mechanical properties and scratch resistance
JP4850824B2 (ja) 2004-03-09 2012-01-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 慢性炎症性疾患の治療のためのサイトカイン生成のインヒビターとしての３−‘４−複素環−１，２，３−トリアゾール−１−イル−ｎ−アリール−ベンズアミド
MXPA06011799A (es) 2004-04-12 2006-12-15 Sankyo Co Derivados de tienopiridina.
JP2005325099A (ja) 2004-04-12 2005-11-24 Sankyo Co Ltd チエノピリジン誘導体
US7981229B2 (en) 2004-06-04 2011-07-19 Cornerstone Research Group, Inc Method of making and using shape memory polymer patches
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
WO2006048266A2 (en) 2004-11-04 2006-05-11 Roche Diagnostics Gmbh Gene expression profiling of leukemias with mll gene rearrangements
WO2006048264A2 (en) 2004-11-04 2006-05-11 Roche Diagnostics Gmbh Gene expression profiling in acute lymphoblastic leukemia (all), biphenotypic acute leukemia (bal), and acute myeloid leukemia (aml) m0
US20070155884A1 (en) 2004-11-12 2007-07-05 Basell Poliolefine Italia S.R.L. Filled olefin polymer compositions having improved mechanical properties and scratch resistance
US8000795B2 (en) 2004-12-17 2011-08-16 Lozano Andres M Cognitive function within a human brain
WO2006074226A2 (en) 2005-01-05 2006-07-13 Novacea, Inc. Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
CA2593264C (en) 2005-01-19 2012-09-25 Merck & Co., Inc. Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006096649A2 (en) 2005-03-05 2006-09-14 Harc (Houston Advanced Research Center) Methods and biomarkers for detecting nanoparticle exposure
CA2599899A1 (en) 2005-03-09 2006-09-21 Schering Corporation Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
WO2006132928A2 (en) 2005-06-03 2006-12-14 Case Western Reserve University Methods and compositions for treating inflammation
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070059265A1 (en) * 2005-06-28 2007-03-15 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss and/or for increasing the density of keratin fibers
US20070071699A1 (en) 2005-06-28 2007-03-29 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening
JP2009502115A (ja) 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 小細胞肺癌の診断方法
WO2007019180A2 (en) 2005-08-04 2007-02-15 Science & Technology Corporation @ Unm Compounds for binding to eralpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof
US20070049603A1 (en) 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof
AR056200A1 (es) 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US20070078175A1 (en) 2005-10-05 2007-04-05 L'oreal Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof
WO2007072095A1 (en) 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
WO2007101224A2 (en) 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use
JP2009528289A (ja) 2006-02-27 2009-08-06 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
WO2007127183A1 (en) 2006-04-26 2007-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
WO2008063671A2 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US20100120732A1 (en) * 2007-03-09 2010-05-13 Kowa Co., Ltd. Agent for prevention and/or treatment of systemic lupus erythematosus
WO2008110196A1 (en) 2007-03-09 2008-09-18 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
WO2009029669A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
AR060498A1 (es) 2007-04-17 2008-06-18 Richter Gedeon Vegyeszet Compuestos de tieno [2,3-b] piridinas
MX2009013729A (es) 2007-06-14 2010-01-25 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa.
KR100901127B1 (ko) 2007-06-22 2009-06-08 한국과학기술연구원 독소루비신 처리에 따른, 심장독성 유발 약물 검색용마커유전자 및 이를 이용한 심장독성 유발 약물 검색 방법
US20090007243A1 (en) 2007-06-27 2009-01-01 Trusteer Ltd. Method for rendering password theft ineffective
WO2009009669A2 (en) 2007-07-10 2009-01-15 The Trustees Of Columbia University In The City Of New York Thermostabilization of proteins
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
WO2009073460A2 (en) 2007-12-03 2009-06-11 Bausch & Lomb Incorporated Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2249852B1 (en) 2008-02-15 2014-12-24 Novobion Oy Soluble complexes of curcumin
EP3028743A3 (en) 2008-03-05 2017-01-25 Vicus Therapeutics, LLC Compositions for mucositis and oncology therapies
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US7629112B1 (en) 2008-05-30 2009-12-08 Eastman Kodak Company Color photographic materials with yellow minimum density colorants
JP5180882B2 (ja) 2008-07-29 2013-04-10 株式会社プライムポリマー ポリプロピレン樹脂組成物、およびその成形体
RU2011110908A (ru) * 2008-08-26 2012-10-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Тиенопиримидины для фармацевтических композиций
US20100093764A1 (en) 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010077101A2 (ko) 2008-12-30 2010-07-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
US8367663B2 (en) 2009-01-08 2013-02-05 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
SG172898A1 (en) 2009-02-13 2011-08-29 Bayer Schering Pharma Ag Fused pyrimidines
EP2411526A4 (en) 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF GANGLIOSID BIOSYNTHESIS
KR20100137090A (ko) 2009-06-22 2010-12-30 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
MX2012000434A (es) 2009-07-09 2012-04-11 Crescendo Therapeutics Llc Metodo de sanacion de herida y modulacion de cicatriz.
HRP20150066T1 (hr) 2009-09-29 2015-02-27 Board Of Regents Of The University Of Texas System Anti-malarijski agensi koji su inhibitori dihidroorotat dehidrogenaze
EP2308883A1 (en) 2009-10-05 2011-04-13 Centre National De La Recherche Scientifique New derivatives of thieno[2,3-b]pyridine and 5,6,7,8 tetrahydrothieno[2,3 b]quinoline in particular useful in the treatment of malaria
WO2011094847A1 (en) 2010-02-04 2011-08-11 Penn Linda Z Methods and compositions for diagnosing and treating patients having multiple myeloma that respond to statin therapy
CN102811730B (zh) 2010-02-08 2014-07-09 杜涛 孕激素作为糖皮质激素增敏剂的使用
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201107197D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
JP6051632B2 (ja) 2011-07-20 2016-12-27 日立化成株式会社 研磨剤及び基板の研磨方法
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
ES2650230T3 (es) 2011-09-23 2018-01-17 Academisch Medisch Centrum Materiales y métodos para pronóstico de evolución de esófago de Barrett
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
GB201120993D0 (en) 2011-12-06 2012-01-18 Imp Innovations Ltd Novel compounds and their use in therapy
WO2013088853A1 (ja) * 2011-12-15 2013-06-20 国立大学法人東京農工大学 オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター
CA2861462A1 (en) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity modulating tricyclic compounds
KR101370670B1 (ko) 2012-03-12 2014-03-06 조선대학교산학협력단 플라본 화합물의 15-하이드록시프로스타글란딘 탈수소효소 활성의 억제 효능 및 그의 용도
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
KR101244964B1 (ko) 2012-05-30 2013-03-18 조선대학교산학협력단 15-히드록시프로스타글란딘 디히드로게나제 및 ｐｇｅ2 활성을 조절하는 황칠나무 추출물의 용도
EP2922543B1 (en) 2012-11-20 2017-05-24 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as pde10 inhibitors
WO2014081878A2 (en) 2012-11-21 2014-05-30 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2014160947A1 (en) 2013-03-29 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof
CN105339425B (zh) 2013-07-08 2018-04-10 普瑞曼聚合物株式会社 丙烯系树脂组合物
WO2015048245A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
WO2015077382A2 (en) 2013-11-19 2015-05-28 Fight Against Cancer Innovation Trust Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
EP3131881A4 (en) 2014-04-18 2017-09-06 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
US10117842B2 (en) 2014-08-12 2018-11-06 The University Of Pécs (Pécsi Tudományegyetem) Methods and materials for reducing ischemia-reperfusion injury
KR102255308B1 (ko) * 2014-11-18 2021-05-24 삼성전자주식회사 아세틸살리실산을 포함하는 개체의 스테로이드 부작용을 예방 또는 치료하기 위한 조성물 및 그의 용도
AU2015369624A1 (en) 2014-12-23 2017-06-08 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CN118059093A (zh) 2015-03-08 2024-05-24 卡斯西部储备大学 用于治疗纤维症的短链脱氢酶活性的抑制剂
US9918965B2 (en) 2015-04-10 2018-03-20 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
AU2016248080A1 (en) 2015-04-14 2017-11-02 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
PL3095818T3 (pl) 2015-05-22 2019-09-30 Borealis Ag Kompozyt polipropylen-włókno węglowe
PL3095820T3 (pl) 2015-05-22 2019-10-31 Borealis Ag Kompozycja polimerowa wzmacniana włóknami
CN109072186B (zh) 2016-03-04 2023-06-23 莱兰斯坦福初级大学评议会 利用前列腺素e2进行肌肉再生的组合物和方法
JP7139308B2 (ja) 2016-07-18 2022-09-20 ケース ウエスタン リザーブ ユニバーシティ 神経新生の促進及びニュ－ロン細胞死の阻害のための短鎖脱水素酵素活性の阻害剤
CN110462026B (zh) 2016-11-30 2024-02-06 巴斯德研究所 人先天性淋巴细胞前体：鉴定、表征、应用
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
EP3576737A4 (en) 2017-02-06 2021-04-21 Case Western Reserve University COMPOSITIONS AND METHODS OF MODULATING THE ACTIVITY OF SHORT CHAIN DEHYDROGENASE
EP3606520A4 (en) 2017-04-07 2021-01-06 Case Western Reserve University INHIBITORS OF SHORT CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF CORONARY DISEASES
CN111132982A (zh) 2017-05-26 2020-05-08 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
KR102698911B1 (ko) 2017-06-09 2024-08-23 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 근육 질환을 예방하거나 치료하기 위한 조성물 및 방법
WO2019010482A1 (en) 2017-07-07 2019-01-10 Case Western Reserve University COMPOSITIONS AND METHODS FOR MODULATING COLUMN MATURATION
JP2019066312A (ja) 2017-09-29 2019-04-25 ミネベアミツミ株式会社 ひずみゲージ
EP3781154A4 (en) 2018-04-04 2022-02-23 Case Western Reserve University COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY INJURY
IL277978B2 (en) 2018-04-25 2024-07-01 Bayer Ag Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
GB201807968D0 (en) 2018-05-16 2018-07-04 Naturex Sa Eutectic extract formation and purification
KR102528290B1 (ko) 2018-08-24 2023-05-03 썬전 샥 컴퍼니 리미티드 안경
EP3847159A2 (en) 2018-09-04 2021-07-14 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
EP3883577A4 (en) 2018-11-21 2022-06-15 Case Western Reserve University COMPOSITIONS AND METHODS FOR MODULATION OF SHORT CHAIN DEHYDROGENASE ACTIVITY
EP3917911A1 (en) 2019-01-31 2021-12-08 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
WO2021168430A1 (en) 2020-02-21 2021-08-26 Case Western Reserve University Compositions and methods for treating renal injury
US20220304992A1 (en) 2019-06-11 2022-09-29 The Board Of Trustees Of The Leland Stanford Junior University Methods of rejuvenating aged tissue by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-pgdh)
AU2021211732A1 (en) 2020-01-23 2022-08-25 Myoforte Therapeutics, Inc. PGDH inhibitors and methods of making and using
CA3183262A1 (en) 2020-05-20 2021-11-25 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
WO2021252936A1 (en) 2020-06-11 2021-12-16 The Board Of Trustees Of The Leland Stanford Junior University Rejuvenation of aged tissues and organs by inhibition of the pge2 degrading enzyme, 15-pgdh
WO2022032230A1 (en) 2020-08-07 2022-02-10 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536855A (ja) 2005-04-15 2008-09-11 ジェネンテック・インコーポレーテッド 炎症性腸疾患（ｉｂｄ）の治療
JP2015514770A (ja) 2012-04-16 2015-05-21 ケース ウエスタン リザーブ ユニバーシティ １５−ｐｇｄｈ活性を調節する組成物および方法
WO2015065716A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ａｒｃｈｉｖｅｓ ｏｆ Ｂｉｏｃｈｅｍｉｓｔｒｙ ａｎｄ Ｂｉｏｐｈｙｓｉｃｓ，２００５年，Ｖｏｌ．４３５，ｐｐ．５０－５５

Also Published As

Publication number Publication date
US11690847B2 (en) 2023-07-04
JP2020502070A (ja) 2020-01-23
US20200061073A1 (en) 2020-02-27
EP3548035A4 (en) 2020-07-22
WO2018102552A1 (en) 2018-06-07
US20230355636A1 (en) 2023-11-09
EP3548035A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
JP7595413B2 (ja) １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
AU2021204985B2 (en) Compositions and methods of modulating 15-pgdh activity
AU2012333986B2 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
JP7178360B2 (ja) 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤
EP2776426A1 (en) New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
CA3068445A1 (en) Compositions and methods of modulating short-chain dehydrogenase activity
JP7773988B2 (ja) アンジオテンシンｉｉに関連する疾患の治療における使用のためのイミダゾリルチオフェンスルホニルカルバメート
US12441718B2 (en) Selective angiotensin II compounds
JP2023539614A (ja) アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物
CN100491355C (zh) 带有五元环基团的环状二胺化合物
WO2024149712A1 (en) Selective angiotensin ii compounds
HK40081690B (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
HK40081690A (en) Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
HK1197241B (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221212

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230126

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230131

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230310

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241126

R150 Certificate of patent or registration of utility model

Ref document number: 7595413

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150